Premium
Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials
Author(s) -
Partridge A.C.R.,
Bai J.W.,
Rosen C.F.,
Walsh S.R.,
Gulliver W.P.,
Fleming P.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16485
Subject(s) - medicine , infliximab , randomized controlled trial , ciclosporin , adverse effect , inflammatory bowel disease , pyoderma gangrenosum , placebo , surgery , observational study , clinical trial , crohn's disease , clinical endpoint , canakinumab , dermatology , anakinra , chemotherapy , disease , pathology , alternative medicine
Summary Background Pyoderma gangrenosum ( PG ) is a neutrophilic dermatosis with substantial morbidity. There is no consensus on gold‐standard treatments. Objectives To review the effectiveness of systemic therapy for PG . Methods We searched six databases for 24 systemic therapies for PG . Primary outcomes were complete healing and clinical improvement; secondary outcomes were time to healing and adverse effects. Results We found 3326 citations and 375 articles underwent full‐text review; 41 studies met the inclusion criteria. There were 704 participants in 26 retrospective cohort studies, three prospective cohort studies, seven case series, one case–control study, two open‐label trials and two randomized controlled trials ( RCT s). Systemic corticosteroids were the most studied (32 studies), followed by ciclosporin (21 studies), biologics (16 studies) and oral dapsone (11 studies). One RCT ( STOP ‐ GAP , n = 121) showed that prednisolone and ciclosporin were similar: 15–20% of patients showed complete healing at 6 weeks and 47% at 6 months. Another RCT ( n = 30) found that infliximab was superior to placebo at 2 weeks (46% vs. 6% response), with a 21% complete healing rate at 6 weeks. Two uncontrolled trials showed 60% and 37% healing within 4 months for canakinumab and infliximab, respectively; other data suggest that patients with concurrent inflammatory bowel disease may benefit from biologics. The remaining studies were poor quality and had small sample sizes but supported the use of corticosteroids, ciclosporin and biologics. Conclusions Systemic corticosteroids, ciclosporin, infliximab and canakinumab had the most evidence in treating PG . However, current literature is limited to small and lower‐quality studies with substantial heterogeneity.